Management of carcinoma in situ of the bladder: best practice and recent developments
Open Access
- 21 August 2015
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 7 (6), 351-364
- https://doi.org/10.1177/1756287215599694
Abstract
Management of carcinoma in situ of the bladder remains a complex and challenging endeavor due to its high rate of recurrence and progression. Although it is typically grouped with other nonmuscle invasive bladder cancers, its higher grade and aggressiveness make it a unique clinical entity. Intravesical bacillus Calmette-Guérin is the standard first-line treatment given its superiority to other agents. However, high rates of bacillus Calmette-Guérin failure highlight the need for additional therapies. Radical cystectomy has traditional been the standard second-line therapy, but additional intravesical therapies may be more appealing for non-surgical candidates and patients refusing cystectomy. The subject of this review is the treatment strategies and available therapies currently available for carcinoma in situ of the bladder. It discusses alternative intravesical treatment options for patients whose condition has failed to respond to bacillus Calmette-Guérin therapy and who are unfit or unwilling to undergo cystectomy.Keywords
This publication has 94 references indexed in Scilit:
- SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-GuérinJournal of Urology, 2013
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013European Urology, 2013
- Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of MaintenanceEuropean Urology, 2013
- A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder CancerJournal of Urology, 2012
- Factors Affecting Response to Bacillus Calmette-Guérin Plus Interferon for Urothelial Carcinoma in SituJournal of Urology, 2011
- A Phase I Trial of Intravesical Nanoparticle Albumin-Bound Paclitaxel in the Treatment of Bacillus Calmette-Guérin Refractory Nonmuscle Invasive Bladder CancerJournal of Urology, 2011
- Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder CancerJournal of Urology, 2010
- Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder CancerCancer Prevention Research, 2009
- Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working partyWorld Journal of Urology, 2009
- FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancerThe Journal of Pathology, 2007